Non-alcoholic fatty liver disease classification

Non-Alcoholic Fatty Liver Disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case studies
Case #1
Non-alcoholic fatty liver disease classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Non-alcoholic fatty liver disease classification
CDC on Non-alcoholic fatty liver disease classification
Non-alcoholic fatty liver disease classification in the news
Blogs on Non-alcoholic fatty liver disease classification
Directions to Hospitals Treating Non-alcoholic fatty liver disease
Risk calculators and risk factors for Non-alcoholic fatty liver disease classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

NAFLD may be classified into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).

Classification

• Based on histology it is classified into the non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH).
• NAFL mostly considered as a benign condition but recent studies show it can progress to NASH up to 44%.
• The more severe form of NAFLD is called non-alcoholic steatohepatitis (NASH).
• One of the leading cause of cirrhosis in adults in united states is NASH. Almost 25 percent of adults with NASH may lead to cirrhosis.
• On the other hand, NASH progress to fibrosis that can lead to cirrhosis and hepatocellular cancer (HCC).
• Rate of progression does not correlate with body mass index (BMI) or hyperlipidemia